ÂÜÀòÂÒÂ×

Dr. Kuhlen has extensive depth and breadth of expertise as General Counsel for biotechnology companies, where he has been responsible for legal, SEC, human resources, intellectual property, and corporate governance functions. Dr. Kuhlen was most recently General Counsel and Secretary at Synthorx, Inc., where he led the legal aspects of its $150 million initial public offering and advised on the company’s subsequent $2.5 billion acquisition by Sanofi. Prior to Synthorx, Dr. Kuhlen was General Counsel at Ignyta, Inc., where he coordinated two public financings and advised on the company’s $1.7 billion acquisition by Roche. Before Ignyta, Dr. Kuhlen served as General Counsel of Genoptix, Inc., where he led the legal function from its initial public offering to its successful acquisition by Novartis. Prior to Genoptix, he was an attorney in private practice with Cooley LLP. Dr. Kuhlen holds a B.S. in biochemistry and cell biology and a B.A. in economics from the University of California, San Diego, and a M.D. and J.D. from the University of Southern California.